This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Floras, J. S. Articles by Mark, A. L. Search for Related Content PubMed PubMed Citation Articles by Floras, J. S. Articles by Mark, A. L.

Hypertension, Vol 10, 409-416, Copyright © 1987 by American Heart Association

ARTICLES

Inhibition of muscle sympathetic nerve activity in humans by arginine vasopressin

JS Floras, PE Aylward, FM Abboud and AL Mark
Department of Internal Medicine, University of Iowa College of Medicine, Iowa City.

Arginine vasopressin, a potent vasoconstrictor, does not raise arterial pressure in normal humans even at pathophysiological plasma levels. To examine whether the pressor effect of vasopressin in humans is buffered by baroreceptor reflex inhibition of sympathetic nerve activity, we recorded postganglionic muscle sympathetic nerve activity directly from the peroneal nerve in 12 normal men before, during, and after a 20- minute intravenous infusion of vasopressin, 4 ng/kg/min, that increased mean plasma concentrations from 6.2 +/- 0.6 to 320 +/- 68 (SE) pg/ml. During the first 5 minutes (n = 8), mean arterial pressure increased from 91 +/- 3 to 97 +/- 4 mm Hg (p less than 0.05) and integrated sympathetic nerve activity decreased from 271 +/- 45 to 156 +/- 33 units (p less than 0.05). At 15 minutes (n = 12), arterial pressure did not differ from control values whereas forearm vascular resistance fell (p less than 0.05) and central venous pressure and heart rate increased (p less than 0.05). Sympathetic nerve activity remained below control levels throughout the infusion (202 +/- 31 vs 254 +/- 40 units before infusion; p less than 0.05). An effect of vasopressin on ganglionic transmission was excluded, since the sympathoexcitatory response to apnea was not attenuated during vasopressin. Thus, pathophysiologic levels of vasopressin in humans cause inhibition of muscle sympathetic nerve activity that is not due to a ganglionic blocking action. The sympathoinhibition may be caused in part by the modest increases in mean arterial and central venous pressures and attendant stimulation of arterial and cardiac baroreceptors. The reflex decrease in sympathetic nerve activity would be expected to buffer the direct vasoconstrictor effects of vasopressin.

This article has been cited by other articles:

				J. P. Greenwood, E. M. Scott, J. B. Stoker, J. J. Walker, and D. A.S.G. Mary Sympathetic Neural Mechanisms in Normal and Hypertensive Pregnancy in Humans Circulation, October 30, 2001; 104(18): 2200 - 2204. [Abstract] [Full Text] [PDF]

				Y. Hirata, H. Hayakawa, M. Kakoki, A. Tojo, E. Suzuki, D. Nagata, K. Kimura, A. Goto, K. Kikuchi, T. Nagano, et al. Receptor Subtype for Vasopressin-Induced Release of Nitric Oxide From Rat Kidney Hypertension, January 1, 1997; 29(1): 58 - 64. [Abstract] [Full Text]